Reata Pharmaceuticals Inc (Nasdaq: RETA) has received a USD30m milestone payment from its licensee, Kyowa Hakko Kirin Co Ltd, following the start of a clinical trial in Japan, the biopharmaceutical company revealed on Thursday.
The Phase 3 AYAME trial will assess the efficacy and safety of bardoxolone methyl (bardoxolone) for the treatment of diabetic kidney disease.
Reata granted Kyowa Hakko Kirin an exclusive licence in December 2009 to develop and commercialise bardoxolone in renal disease and certain other indications in Japan, China, Taiwan, South Korea and Southeast Asia. Last year, the Japanese company reported positive results from the Phase 2 TSUBAKI trial of bardoxolone in patients with type 2 diabetes and chronic kidney disease.
Around 700 diabetic kidney disease patients will take part in the Phase 3 trial, which is expected to be completed in March 2022.
Kyowa Hakko Kirin is also collaborating with Reata in Japan on the ongoing Phase 3 CARDINAL trial of bardoxolone for the treatment of Alport syndrome, a severe, hereditary form of chronic kidney disease.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes